{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T12:10:49Z","timestamp":1760443849436,"version":"build-2065373602"},"reference-count":49,"publisher":"Jaypee Brothers Medical Publishing","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.59556\/japi.73.1124","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T11:28:31Z","timestamp":1760441311000},"page":"e28-e37","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Cyclophosphamide and Immunosuppressants in Systemic Sclerosis-associated Interstitial Lung Disease: A Meta-analysis"],"prefix":"10.59556","volume":"73","author":[{"given":"Isha","family":"Anwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darryl","family":"Sony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Chetry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Hatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Chandrashekara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","reference":[{"key":"key20251014112717_B1","doi-asserted-by":"crossref","unstructured":"Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354(25):2655\u20132666.","DOI":"10.1056\/NEJMoa055120"},{"key":"key20251014112717_B2","doi-asserted-by":"crossref","first-page":"109267.","DOI":"10.1016\/j.clim.2023.109267","article-title":"Global, regional, and national incidence and prevalence of systemic sclerosis.","volume":"248:","author":"Tian","year":"2023;","journal-title":"Clin Immunol"},{"issue":"(7):","key":"key20251014112717_B3","doi-asserted-by":"crossref","first-page":"3121\u2013","DOI":"10.1093\/rheumatology\/keab190","article-title":"Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis.","volume":"60","author":"Bairkdar","year":"2021;","journal-title":"Rheumatology (Oxford)"},{"issue":"(11):","key":"key20251014112717_B4","doi-asserted-by":"crossref","first-page":"1147\u2013","DOI":"10.1016\/j.autrev.2017.09.010","article-title":"Humanistic and cost burden of systemic sclerosis: a review of the literature.","volume":"16","author":"Fischer","year":"2017;","journal-title":"Autoimmun Rev"},{"issue":"(Suppl 3):","key":"key20251014112717_B5","doi-asserted-by":"crossref","first-page":"A499.","DOI":"10.1136\/annrheumdis-2013-eular.1499","article-title":"FRI0372 Early mortality in systemic sclerosis: rationale for forming a multinational inception cohort of patients with scleroderma (the insync study).","volume":"72","author":"Nikpour","year":"2013;","journal-title":"Ann Rheum Dis"},{"issue":"(5):","key":"key20251014112717_B6","doi-asserted-by":"crossref","first-page":"1067\u2013","DOI":"10.1002\/art.40027","article-title":"Early mortality in a multinational systemic sclerosis inception cohort.","volume":"69","author":"Hao","year":"2017;","journal-title":"Arthritis Rheumatol"},{"issue":"(2):","key":"key20251014112717_B7","doi-asserted-by":"crossref","first-page":"422\u2013","DOI":"10.1378\/chest.13-2626","article-title":"Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review.","volume":"146","author":"Winstone","year":"2014;","journal-title":"Chest"},{"issue":"(1):","key":"key20251014112717_B8","doi-asserted-by":"crossref","first-page":"e001291.","DOI":"10.1136\/bmjresp-2022-001291","article-title":"Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review.","volume":"10","author":"Gupta","year":"2023;","journal-title":"BMJ Open Respir Res"},{"issue":"(2):","key":"key20251014112717_B9","doi-asserted-by":"crossref","first-page":"235\u2013","DOI":"10.3899\/jrheum.170307","article-title":"All-cause healthcare costs and mortality in patients with systemic sclerosis with lung involvement.","volume":"45","author":"Fischer","year":"2018;","journal-title":"J Rheumatol"},{"issue":"(8):","key":"key20251014112717_B10","doi-asserted-by":"crossref","first-page":"2205\u2013","DOI":"10.1002\/art.39166","article-title":"Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis.","volume":"67","author":"Hoffmann-Vold","year":"2015;","journal-title":"Arthritis Rheumatol"},{"issue":"(10):","key":"key20251014112717_B11","doi-asserted-by":"crossref","first-page":"1809\u2013","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.","volume":"69","author":"Tyndall","year":"2010;","journal-title":"Ann Rheum Dis"},{"issue":"(4):","key":"key20251014112717_B12","doi-asserted-by":"crossref","first-page":"249\u2013","DOI":"10.5114\/reum.2018.77977","article-title":"Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management.","volume":"56","author":"Chowaniec","year":"2018;","journal-title":"Reumatologia"},{"issue":"(3):","key":"key20251014112717_B13","doi-asserted-by":"crossref","first-page":"549\u2013","DOI":"10.1016\/j.ccm.2004.05.009","article-title":"Interstitial lung disease in the patient who has connective tissue disease.","volume":"25","author":"Strange","year":"2004;","journal-title":"Clin Chest Med"},{"issue":"(2):","key":"key20251014112717_B14","doi-asserted-by":"crossref","first-page":"371\u2013","DOI":"10.1016\/S0889-857X(03)00025-5","article-title":"Interstitial lung disease in scleroderma.","volume":"29","author":"White","year":"2003;","journal-title":"Rheum Dis Clin North Am"},{"issue":"(8):","key":"key20251014112717_B15","doi-asserted-by":"crossref","first-page":"1327\u2013","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis.","volume":"76","author":"Kowal-Bielecka","year":"2017;","journal-title":"Ann Rheum Dis"},{"issue":"(1):","key":"key20251014112717_B16","doi-asserted-by":"crossref","first-page":"42\u2013","DOI":"10.1016\/j.semarthrit.2012.01.003","article-title":"Treatment of systemic sclerosis complications: what to use when first-line treatment fails\u2014a consensus of systemic sclerosis experts.","volume":"42","author":"Walker","year":"2012;","journal-title":"Semin Arthritis Rheum"},{"issue":"(2):","key":"key20251014112717_B17","doi-asserted-by":"crossref","first-page":"137\u2013","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American Thoracic Society Clinical Practice Guideline.","volume":"209","author":"Raghu","year":"2024;","journal-title":"Am J Respir Crit Care Med"},{"issue":"(2):","key":"key20251014112717_B18","doi-asserted-by":"crossref","first-page":"317\u2013","DOI":"10.1513\/AnnalsATS.202301-055OC","article-title":"Rituximab in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis.","volume":"21","author":"Macrea","year":"2024;","journal-title":"Ann Am Thorac Soc"},{"key":"key20251014112717_B19","author":"New ACR Guideline Summaries: Screen, Monitor and Treat ILD;","year":"2023."},{"key":"key20251014112717_B20","doi-asserted-by":"crossref","first-page":"n71.","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372:","author":"Page","year":"2021;","journal-title":"BMJ"},{"key":"key20251014112717_B21","volume-title":"Statistics,","author":"Freedman","year":"2007.","edition":"4th ed."},{"key":"key20251014112717_B22","volume-title":"Introductory Statistics,","author":"Weiss","year":"2014.","edition":"10th ed."},{"issue":"(1):","key":"key20251014112717_B23","doi-asserted-by":"crossref","first-page":"1\u2013","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996;","journal-title":"Control Clin Trials"},{"issue":"(11):","key":"key20251014112717_B24","doi-asserted-by":"crossref","first-page":"982\u2013","DOI":"10.7326\/0003-4819-135-11-200112040-00010","article-title":"Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses.","volume":"135","author":"Kjaergard","year":"2001;","journal-title":"Ann Intern Med"},{"key":"key20251014112717_B25","unstructured":"Ottawa Hospital Research Institute. [Internet] 2024. Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"key20251014112717_B26","first-page":"603\u2013","article-title":"The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of case-control studies in meta-analyses.","volume":"25:","author":"Wells","year":"2011;","journal-title":"Eur J Epidemiol"},{"key":"key20251014112717_B27","doi-asserted-by":"crossref","DOI":"10.1002\/9780470743386","volume-title":"Introduction to Meta-Analysis.","author":"Borenstein","year":"2009."},{"issue":"(2):","key":"key20251014112717_B28","doi-asserted-by":"crossref","first-page":"205\u2013","DOI":"10.1007\/s10067-005-1157-y","article-title":"A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis.","volume":"25","author":"Nadashkevich","year":"2006;","journal-title":"Clin Rheumatol"},{"issue":"(12):","key":"key20251014112717_B29","doi-asserted-by":"crossref","first-page":"1691\u2013","DOI":"10.1007\/s00296-014-3026-y","article-title":"Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement\u2014a retrospective study.","volume":"34","author":"Poormoghim","year":"2014;","journal-title":"Rheumatol Int"},{"issue":"(1):","key":"key20251014112717_B30","doi-asserted-by":"crossref","first-page":"123.","DOI":"10.1186\/s13075-016-1015-0","article-title":"Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.","volume":"18","author":"Shenoy","year":"2016;","journal-title":"Arthritis Res Ther"},{"issue":"(5):","key":"key20251014112717_B31","doi-asserted-by":"crossref","first-page":"483\u2013","DOI":"10.1007\/s00408-013-9499-8","article-title":"Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.","volume":"191","author":"Panopoulos","year":"2013;","journal-title":"Lung"},{"issue":"(12):","key":"key20251014112717_B32","doi-asserted-by":"crossref","first-page":"2106\u2013","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.","volume":"57","author":"Sircar","year":"2018;","journal-title":"Rheumatology (Oxford)"},{"issue":"(10):","key":"key20251014112717_B33","doi-asserted-by":"crossref","first-page":"4071\u2013","DOI":"10.1007\/s10067-021-05785-6","article-title":"Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis-related interstitial lung diseases: a retrospective, observational cohort study.","volume":"40","author":"Y\u0131lmaz","year":"2021;","journal-title":"Clin Rheumatol"},{"issue":"(12):","key":"key20251014112717_B34","doi-asserted-by":"crossref","first-page":"3962\u2013","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.","volume":"54","author":"Hoyles","year":"2006;","journal-title":"Arthritis Rheum"},{"key":"key20251014112717_B35","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Available from: https:\/\/training.cochrane.org\/handbook."},{"key":"key20251014112717_B36","doi-asserted-by":"crossref","first-page":"13.","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD).","volume":"20:","author":"Cottin","year":"2019;","journal-title":"Respir Res"},{"issue":"(12):","key":"key20251014112717_B37","doi-asserted-by":"crossref","first-page":"102978.","DOI":"10.1016\/j.autrev.2021.102978","article-title":"Pharmacological treatments for SSc-ILD: systematic review and critical appraisal of the evidence.","volume":"20","author":"Vonk","year":"2021;","journal-title":"Autoimmun Rev"},{"issue":"(5):","key":"key20251014112717_B38","doi-asserted-by":"crossref","first-page":"R124.","DOI":"10.1186\/ar2534","article-title":"Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies.","volume":"10","author":"Nannini","year":"2008;","journal-title":"Arthritis Res Ther"},{"issue":"(4):","key":"key20251014112717_B39","doi-asserted-by":"crossref","first-page":"306\u2013","DOI":"10.1007\/s10067-004-0906-7","article-title":"Experience with azathioprine in systemic sclerosis associated with interstitial lung disease.","volume":"23","author":"Dheda","year":"2004;","journal-title":"Clin Rheumatol"},{"issue":"(8):","key":"key20251014112717_B40","doi-asserted-by":"crossref","first-page":"3185\u2013","DOI":"10.1007\/s10067-021-05794-5","article-title":"Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.","volume":"40","author":"Ma","year":"2021;","journal-title":"Clin Rheumatol"},{"issue":"(5):","key":"key20251014112717_B41","doi-asserted-by":"crossref","first-page":"625\u2013","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease.","volume":"46","author":"Daoussis","year":"2017;","journal-title":"Semin Arthritis Rheum"},{"issue":"(10):","key":"key20251014112717_B42","doi-asserted-by":"crossref","first-page":"1026\u2013","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.","volume":"176","author":"Tashkin","year":"2007;","journal-title":"Am J Respir Crit Care Med"},{"issue":"(2):","key":"key20251014112717_B43","doi-asserted-by":"crossref","first-page":"291\u2013","DOI":"10.1164\/ajrccm\/144.2.291","article-title":"Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial.","volume":"144","author":"Raghu","year":"1991;","journal-title":"Am Rev Respir Dis"},{"issue":"(12):","key":"key20251014112717_B44","doi-asserted-by":"crossref","first-page":"1537\u2013","DOI":"10.1093\/rheumatology\/kep284","article-title":"Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial\u2014results from the Scleroderma Lung Study.","volume":"48","author":"Khanna","year":"2009;","journal-title":"Rheumatology (Oxford)"},{"issue":"(9):","key":"key20251014112717_B45","doi-asserted-by":"crossref","first-page":"708\u2013","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: scleroderma lung study II (SLS-II), a double-blind, parallel group, randomised controlled trial.","volume":"4","author":"Tashkin","year":"2016;","journal-title":"Lancet Respir Med"},{"issue":"(5):","key":"key20251014112717_B46","doi-asserted-by":"crossref","first-page":"896\u2013","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease.","volume":"156","author":"Huapaya","year":"2019;","journal-title":"Chest"},{"issue":"(3):","key":"key20251014112717_B47","doi-asserted-by":"crossref","first-page":"271\u2013","DOI":"10.1177\/23971983211024410","article-title":"Mycophenolate in scleroderma-associated interstitial lung disease: real-world data from rheumatology and pulmonology clinics in South Asia.","volume":"6","author":"Janardana","year":"2021;","journal-title":"J Scleroderma Relat Disord"},{"issue":"(2):","key":"key20251014112717_B48","doi-asserted-by":"crossref","first-page":"207\u2013","DOI":"10.1007\/s00296-019-04481-8","article-title":"Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.","volume":"40","author":"Naidu","year":"2020;","journal-title":"Rheumatol Int"},{"issue":"(1):","key":"key20251014112717_B49","doi-asserted-by":"crossref","first-page":"45\u2013","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.","volume":"11","author":"Maher","year":"2023;","journal-title":"Lancet Respir Med"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T11:29:08Z","timestamp":1760441348000},"score":1,"resource":{"primary":{"URL":"https:\/\/japi.org\/article\/japi-73-9-e28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.59556\/japi.73.1124"],"URL":"https:\/\/doi.org\/10.59556\/japi.73.1124","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}